|
Published by: CHI Insight Pharma Reports
Published: Nov. 1, 2009 - 224 Pages
Table of Contents
- CHAPTER 1: INTRODUCTION
- 1.1. The Immune System
- 1.2. Scope of the Report
- CHAPTER 2: REVIEW OF MAJOR DISEASES/ CONDITIONS TARGETED BY NEW AND/OR EMERGING IMMUNOTHERAPIES AND VACCINES TO SUPPRESS OR BALANCE THE IMMUNE SYSTEM
- 2.1. Major Autoimmune Diseases
- Rheumatoid Arthritis
- Type 1 Diabetes Mellitus
- Inflammatory Bowel Disease—Crohn’s Disease and Ulcerative Colitis
- Multiple Sclerosis
- Psoriasis
- Psoriatic Arthritis
- Systemic Lupus Erythematosus
- 2.2. Asthma
- 2.3. Allergies
- 2.4. Immune Suppression to Prevent
- Rejection of Organ Transplants
- CHAPTER 3: CURRENT PHARMACOLOGICAL TREATMENT OPTIONS
- 3.1. Major Autoimmune Diseases
- Rheumatoid Arthritis
- Nonsteroidal Anti-inflammatory Drugs
- (NSAIDs)
- Disease-Modifying Antirheumatic
- Drugs (DMARDs)
- Corticosteroids
- Biological Response Modifiers
- Type 1 Diabetes Mellitus
- Inflammatory Bowel Disease—Crohn’s Disease and Ulcerative Colitis
- Multiple Sclerosis
- Interferon-beta
- Copaxone (glatiramer acetate)
- Novantrone (mitoxantrone)
- Tysabri (natalizumab)
- Psoriasis
- Psoriatic Arthritis
- Systemic Lupus Erythematosus
- 3.2. Asthma
- 3.3. Allergies
- 3.4. Immune Suppression to Prevent Rejection of Organ Transplants
- CHAPTER 4: CURRENT AND EMERGING APPROACHES TO SUPPRESS OR BALANCE THE IMMUNE SYSTEM FOR PREVENTION AND TREATMENT OF DISEASE
- CHAPTER 5: EMERGING THERAPIES IN DEVELOPMENT FOR TREATMENT OF MAJOR AUTOIMMUNE DISEASES
- 5.1. Introduction
- 5.2. Abbott Laboratories
- 5.3. Biogen Idec
- 5.4. AstraZeneca
- 5.5. Bristol-Myers Squibb
- 5.6. Centocor Ortho Biotech
- 5.7. Centocor Ortho Biotech and Schering-Plough
- 5.8. Diamyd Medical
- 5.9. Eli Lilly and BioMS Medical
- 5.10. Eli Lilly and MacroGenics
- 5.11. Genzyme and Bayer
- 5.12. GlaxoSmithKline and Genmab
- 5.13. GlaxoSmithKline and Human Genome Sciences
- 5.14. GlaxoSmithKline and Tolerx
- 5.15. GlaxoSmithKline (Selected Additional Product Candidates and Research)
- 5.16. Isotechnika
- 5.17. Merck Serono and ZymoGenetics
- 5.18. Merck Serono
- 5.19. Novartis
- Multiple Sclerosis
- Rheumatoid Arthritis
- Psoriasis
- 5.20. Pfizer
- 5.21. Roche and Chugai Pharmaceutical
- 5.22. Roche and Genentech (A Wholly-Owned Member of the Roche Group)
- 5.23. Sanofi-Aventis
- 5.24. Takeda Pharmaceutical and Millennium Pharmaceuticals
- 5.25. Teva Pharmaceutical Industries and Active Biotech
- 5.26. UCB
- CHAPTER 6: EMERGING THERAPIES FOR TREATMENT OF ASTHMA
- 6.1. Pipeline Overview
- 6.2. Abbott Laboratories and SkyePharma (Also Mundipharma and Kyorin)
- 6.3. Aerovance
- 6.4. Amgen
- 6.5. AstraZeneca
- 6.6. Ception Therapeutics
- 6.7. Genentech
- 6.8. GlaxoSmithKline
- 6.9. Icagen
- 6.10. MediciNova
- 6.11. Pfizer
- 6.12. Schering-Plough and Novartis
- 6.13. Topigen Pharmaceuticals
- 6.14. Wyeth
- CHAPTER 7: SELECTED EXAMPLES OF EMERGING THERAPIES FOR TREATMENT OF ALLERGIES
- 7.1. Introduction
- 7.2. ALK-Abello and Schering-Plough
- 7.3. Allergy Therapeutics
- 7.4. Ception Therapeutics
- 7.5. Cytos Biotechnology
- 7.6. Greer Laboratories
- 7.7. Stallergenes
- CHAPTER 8: IMMUNOTHERAPIES IN DEVELOPMENT FOR PREVENTING REJECTION OF ORGAN TRANSPLANTS
- 8.1. Introduction
- 8.2. APT Pharmaceuticals
- 8.3. Astellas Pharma
- 8.4. Bristol-Myers Squibb
- 8.5. Isotechnika
- 8.6. Novartis
- 8.7. Pfizer
- CHAPTER 9: BUSINESS CONSIDERATIONS —THERAPIES THAT SUPPRESS OR BALANCE THE IMMUNE SYSTEM
- 9.1. Current Market and Market Potential
- 9.2. Competition
- 9.3. Strong Interest on the Part of Major Pharmaceutical Companies
- 9.4. Agreements and Mergers/Acquisitions
- 9.5. Other Major Challenges and Hurdles Being Faced by Companies
- Competition
- Potential Need for Personalized Medicine in at Least Certain Situations
- Targeted Patient Populations
- CHAPTER 10: THOUGHT LEADER INTERVIEWS
- 10.1. David W. Pritchard, President and Chief Executive Officer, KaloBios
- 10.2. Randall C. Schatzman, PhD, President and Chief Executive Officer, Alder Biopharmaceuticals
- 10.3. Louis Vaickus, MD, Chief Medical Officer, Tolerx
- 10.4. Eric H. Zanelli, PhD, Vice President, Research, Peptimmune
- REFERENCES
- COMPANY INDEX WITH WEB ADDRESSES
AbstractThe human immune system can go awry, either attacking an individual’s body or producing an exag-gerated response to a foreign substance that is normally benign. In these situations, immunotherapies are needed to balance or suppress the unwarranted immune response. In this report:
- Approximately 400 product candidates and development programs are identified.
- Current and emerging therapies for selected autoimmune or inflammatory disorders and prevention of organ transplant rejection, directed against a wide range of putative targets, are summarized.
- Specifically, more than 250 emerging autoimmune disease therapies, 80 asthma therapies in development, and 50+ therapy candidates for allergies are covered.
- The strategic consequences of intense competition in a crowded product space are considered.
Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response reviews the problems of insuf-ficient efficacy, side effects, and adverse events associated with the small-molecule and biological drugs available today to treat these disorders. These observations have led to an interest in identifying ways to balance the immune reaction, to suppress the part of the immune response that is causing the disease, while maintaining or enhancing other aspects of the immune system. This report identifies nearly 400 ongoing product candidates and development programs in these indication areas. The companies active in these areas range from multinational pharmaceutical companies with a number of active programs to small boutique start-ups working on a very defined topic.
Get Full Details About This Report >>
|
